Trial Profile

Study of PXL770 and PXL065 in adrenoleukodystrophy (ALD) patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pioglitazone deuterated (Primary) ; PXL 770 (Primary)
Indications Adrenoleucodystrophy
Focus Biomarker; Proof of concept; Therapeutic Use

Most Recent Events

05 Jul 2023 According to Poxel Media Release, the company look forward to initiate this study after secured additional funding.
22 May 2023 New trial record
17 May 2023 According to Poxel Media Release, the company actively pursuing additional financing to initiate this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com